GURU.Markets stock price, segment price, and overall market index valuation
The company's share price 4D Molecular Therapeutics
4D Molecular Therapeutics is a biotech company developing gene therapy. Its stock price is highly volatile, reflecting the hopes and setbacks of its clinical trials, which is typical for companies at this stage.
Share prices of companies in the market segment - Dna
4D Molecular Therapeutics (FDMT) is a biotechnology company developing targeted and evolved adeno-associated virus (AAV)-based vectors for gene therapy. We classify it as a "DNA technology company." The chart below illustrates the dynamics of this cutting-edge, yet risky, biotech sector.
Broad Market Index - GURU.Markets
4D Molecular Therapeutics is a biotech company developing targeted and evolutionary gene therapies to treat a wide range of diseases. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
FDMT - Daily change in the company's share price 4D Molecular Therapeutics
For 4D Molecular, a gene therapy company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to clinical trial news. This metric isn't just noise, but a critical component of the models at System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Dna
4D Molecular Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with FDMT, which focuses on gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
4D is a biopharmaceutical company specializing in gene therapy. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with 4D technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization 4D Molecular Therapeutics
4D Molecular Therapeutics' year-to-date performance is a story of developing a new generation of gene therapy vectors. Its 12-month market cap is entirely dependent on clinical trial data. Positive results for its eye and heart disease treatments fundamentally validate the potential of its unique gene delivery platform.
Annual dynamics of market capitalization of the market segment - Dna
4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapy. Its uniqueness lies in its advanced platform for delivering therapeutic vectors. Its stock price reflects the enormous potential of its technology and the risks associated with clinical trials.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
4D Molecular is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization 4D Molecular Therapeutics
The performance of 4D, a gene therapy company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for eye and lung diseases, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Dna
4D Molecular Therapeutics (4DMT) is a biotechnology company developing a platform for creating optimized gene therapy vectors. Its goal is to improve the delivery of therapeutic genes to target tissues. The gene therapy sector chart reflects overall investor interest in this cutting-edge field and allows one to assess the potential of 4DMT's innovative platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
4D Molecular Therapeutics develops gene therapy. Like most biotech companies, its shares are constantly waiting for breakthrough news. Its stock price is driven by clinical trial results rather than general market trends. This chart clearly demonstrates how scientific developments shape its investment story.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization 4D Molecular Therapeutics
4D Molecular Therapeutics, a gene therapy company developing vectors for precise drug delivery, operates at the forefront of science. Its weekly stock price is reflecting data from clinical and preclinical studies, which underscores investor confidence in its technology platform.
Weekly dynamics of market capitalization of the market segment - Dna
Biotech companies developing gene therapy, like 4D Molecular, are at the forefront of science. News in this field often impacts the entire industry. The chart below illustrates this general sentiment. It allows one to assess how promising the market perceives 4DMT's unique gene delivery platform compared to competing technologies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
4D Molecular Therapeutics is a biotech company developing gene therapy. Its value is determined by the potential of its scientific platform and the results of clinical trials. The chart shows that the company's shares exist in a completely different world from the rest of the market, moving according to its own news calendar.
Market capitalization of the company, segment and market as a whole
FDMT - Market capitalization of the company 4D Molecular Therapeutics
4D Molecular Therapeutics' market capitalization chart reflects investor valuation of its cutting-edge gene therapy delivery platform. Its performance reflects the market's belief that its engineered viral vectors will deliver genes to target tissues more efficiently and safely. Its valuation is a bet on technological superiority in this competitive field.
FDMT - Share of the company's market capitalization 4D Molecular Therapeutics within the market segment - Dna
4D Molecular Therapeutics is a biotech company developing gene therapy using proprietary viral vectors. In the cutting-edge DNA medicine segment, its market capitalization reflects the potential of its platform for precisely targeted gene delivery. The company's market share reflects investors' bet that its technology will be safer and more effective than its competitors.
Market capitalization of the market segment - Dna
Here's a chart reflecting the combined weight of the entire biotech sector specializing in gene therapy. For 4D Molecular Therapeutics, with its proprietary gene delivery platform, this line represents a scientific revolution. The rising chart represents an influx of capital into technologies that promise to treat diseases at the DNA level, where the company aims to become a leader.
Market capitalization of all companies included in a broad market index - GURU.Markets
4D Molecular Therapeutics develops gene therapy using advanced viral vectors for drug delivery. Its market capitalization is determined by the value of its advanced gene transport system. This represents the market share of drug delivery innovations.
Book value capitalization of the company, segment and market as a whole
FDMT - Book value capitalization of the company 4D Molecular Therapeutics
4D Molecular Therapeutics (FDMT) develops gene therapy. Its book value is its financial resources and production base. This consists of cash for clinical trials and its own capacity for producing viral vectors. How has this research and production capital grown? The chart below shows.
FDMT - Share of the company's book capitalization 4D Molecular Therapeutics within the market segment - Dna
4D Molecular Therapeutics is a gene therapy company with its own platform for vector creation. Its scientific breakthroughs require a significant resource base: R&D centers and investments in manufacturing capacity to produce its innovative drugs. The chart shows its share of the physical infrastructure for gene therapy development.
Market segment balance sheet capitalization - Dna
4D Molecular, a gene therapy company, is a capital-intensive business. This requires owning cutting-edge R&D centers and building its own production facilities. The BCap_Seg chart for the biotech sector shows that developing breakthrough technologies requires a significant financial base.
Book value of all companies included in the broad market index - GURU.Markets
4D Molecular Therapeutics' balance sheet isn't its factories, but its cutting-edge scientific platform for creating and delivering gene therapies (AAV vectors). The company's assets are its intellectual capital and clinical trial data. The chart shows how this intangible yet valuable R&D asset compares to big pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - 4D Molecular Therapeutics
4DMT's balance sheet is its R&D capital. Its entire market value is a premium for its platform for creating gene therapy vectors. Its price is a bet that its drug delivery system will outperform its competitors.
Market to book capitalization ratio in a market segment - Dna
4D Molecular Therapeutics is a gene therapy company developing next-generation viral vectors. Its high rank on this chart reflects its unique technology platform, which could make gene therapy more effective and safer for patients.
Market to book capitalization ratio for the market as a whole
4D Molecular Therapeutics is a biotech company developing gene therapy using proprietary viral vectors. Its value lies in its unique technological platform. Its market capitalization is a multiple of its book value, reflecting its hopes for the development of a wide range of new drugs.
Debts of the company, segment and market as a whole
FDMT - Company debts 4D Molecular Therapeutics
4D Molecular Therapeutics, a gene therapy company, is using its capital to fund the development and clinical trials of its drug delivery vectors. This chart shows how the biotech company is raising significant funds to advance its innovative platform, which can be applied to treat a wide range of diseases.
Market segment debts - Dna
4D Molecular Therapeutics is a biotech company developing targeted gene therapy. During clinical development, such companies almost always avoid debt due to high risks and lack of revenue. This chart demonstrates that the company, like its peers in the sector, relies solely on equity capital to fund its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio 4D Molecular Therapeutics
4D Molecular Therapeutics develops gene therapy, which requires massive, long-term investments. The financial structure of such companies is always a tale of risk and hope. This chart shows the company's reliance on external funding. It reflects the high stakes placed on a future scientific breakthrough, which is the only path to profitability.
Market segment debt to market segment book capitalization - Dna
4D Molecular Therapeutics is developing a platform for creating optimized gene therapy vectors. This is a cutting-edge but highly complex area of biotechnology. This chart shows how aggressively the sector uses debt to fund R&D, which helps assess how 4DMT finances its research.
Debt to book value of all companies in the market
4D Molecular Therapeutics develops gene therapy, one of the most capital-intensive and risky areas in biotechnology. This chart, showing the market's overall debt load, provides investors with a benchmark. It helps them assess how the company's capital raising strategy aligns with the extreme risks and potential of its research.
P/E of the company, segment and market as a whole
P/E - 4D Molecular Therapeutics
4D Molecular Therapeutics is a biotechnology company developing targeted and evolutionary gene therapies. This chart shows how the market values its innovative gene delivery platform. This assessment is based on the potential of its carrier vectors to deliver therapeutic genes precisely to the desired tissues, increasing the efficacy and safety of treatment.
P/E of the market segment - Dna
4D Molecular Therapeutics is developing advanced gene therapy. This chart shows the average valuation for the biotech sector. It emphasizes that 4DMT is valued not by profits, but by the potential of its gene delivery platform, which the market can value at a significant premium to the average.
P/E of the market as a whole
4D Molecular Therapeutics is a biopharmaceutical company developing targeted and evolutionary gene therapies based on its proprietary platform for creating optimal viral vectors. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether FDMT's high valuation is based on faith in its unique technology platform or is driven by overall sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company 4D Molecular Therapeutics
4D Molecular Therapeutics develops gene therapy using its proprietary platform for delivering therapeutic genes to target tissues. Future profits depend on the success of this technology. This chart shows market expectations regarding the potential of its unique carrier vectors for treating various diseases.
%20P%2FE%204D%20Molecular%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-4D-Molecular-Therapeutics&v=1772513885228 "Chart of the company's future (projected) P/E 4D Molecular Therapeutics")
Future (projected) P/E of the market segment - Dna
4D Molecular Therapeutics (4DMT) is developing a platform for creating optimized adeno-associated viral (AAV) vectors for gene therapy that target specific tissues. The data here reflects analysts' collective bets on the success of its unique delivery technology, reflecting expectations that its approach will make gene therapy more effective.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513885232 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
4D Molecular Therapeutics develops viral vectors for gene therapy, aiming to create more effective and safe treatments. This general sentiment chart shows how willing investors are to fund companies working on fundamental technology platforms in biotech.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513885234 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit 4D Molecular Therapeutics
4D Molecular Therapeutics is developing a platform for creating optimized gene therapy vectors that target specific tissues. This chart illustrates the financial side of cutting-edge biotechnology. It reflects investments in developing more efficient and safe gene delivery methods for treating various diseases.
Profit of companies in the market segment - Dna
4D Molecular Therapeutics is a biopharmaceutical company developing gene therapy. Its unique platform enables the creation of tissue-targeted vectors, improving efficacy and safety. Currently in the clinical stage, its future profitability depends on the success of this cutting-edge technology.
Overall market profit
4D Molecular Therapeutics is a biotech company developing gene therapy. Its value and prospects depend on the success of its scientific platform and clinical trials. While there's no direct correlation with the economy, the overall market conditions, reflected in this chart, critically impact the company's ability to raise the significant capital needed for its development.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company 4D Molecular Therapeutics
4D Molecular Therapeutics is a gene therapy company using a proprietary platform to create and deliver vectors for the treatment of various diseases. This chart shows analysts' speculative expectations. Future profits are entirely dependent on the success of its clinical programs in ophthalmology, cardiology, and pulmonology.
%20profit%20of%20the%20company%204D%20Molecular%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-4D-Molecular-Therapeutics&v=1772513885437 "Graph of future (projected) profit of the company 4D Molecular Therapeutics")
Future (predicted) profit of companies in the market segment - Dna
4D Molecular Therapeutics (4DMT) is a biotech company developing optimized viral vectors for gene therapy. The profitability forecasts for this sector, shown in the graph, demonstrate the enormous interest in this technology. This chart helps assess how 4DMT's advanced platform can improve the delivery and efficacy of gene therapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513885455 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
4D Molecular Therapeutics is a biopharmaceutical company developing targeted gene therapy. Its success depends on progress in clinical trials and its ability to raise capital. The investment climate in the biotech sector is improving amid overall market optimism, which accompanies the positive economic outlook, as shown in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513885476 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - 4D Molecular Therapeutics
4D Molecular Therapeutics (4DMT) is a gene therapy company developing optimized viral vectors for drug delivery. It may not have commercial revenue. This chart shows how highly investors value its technology platform, betting on the development of more effective and safe gene therapies.
P/S market segment - Dna
4D Molecular Therapeutics is a biotechnology company developing a platform for the creation and delivery of optimized gene therapy vectors. This metric reflects the average revenue estimate in the sector and helps understand the premium investors are willing to pay for cutting-edge technology that can improve the efficacy of gene therapy.
P/S of the market as a whole
4D Molecular Therapeutics is a biotech company focused on gene therapy. It has developed a proprietary platform for creating and delivering vectors (carrier viruses) to target tissues. This chart correlates the market's valuation of these companies with their actual revenues, which is important for contextualizing the analysis of cutting-edge, yet early-stage, biotech companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company 4D Molecular Therapeutics
4D Molecular Therapeutics is a gene therapy company with a platform for the creation and delivery of optimized viral vectors. This chart reflects investors' high valuation of its potential future revenue. This valuation is a bet on the superiority of its technology and the success of its clinical programs.
%20P%2FS%204D%20Molecular%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-4D-Molecular-Therapeutics&v=1772513885559 "The graph of the company's future (projected) P/S 4D Molecular Therapeutics")
Future (projected) P/S of the market segment - Dna
4D Molecular Therapeutics (4DMT) is a biopharmaceutical company developing gene therapies based on proprietary vectors (viral shells). This chart compares market expectations for its future revenue with other companies in the DNA technology sector. The valuation reflects investor confidence in the superiority of its gene delivery platform for treating various diseases.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513885638 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
4D Molecular Therapeutics (4DMT) is a biotechnology company developing a gene therapy platform using optimized viral vectors. Its valuation is based on the potential of this technology. This graph of overall market expectations for 4DMT is irrelevant, as its success is determined by scientific breakthroughs, not the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513885641 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales 4D Molecular Therapeutics
This is a revenue chart for 4D Molecular Therapeutics, a biotech company developing gene therapies based on optimized viral vectors. Being in the clinical stage, the company has no commercial revenue. Any revenue reflected in the chart likely comes from partnerships with major pharmaceutical companies supporting its research.
Sales of companies in the market segment - Dna
4D Molecular Therapeutics (4DMT) is a biopharmaceutical company developing optimized viral vectors for gene therapy. Its goal is to create more efficient and safe gene delivery methods. This chart shows revenue in the DNA therapeutics sector. It reflects the cutting edge of gene medicine, where platforms like 4DMT can solve key challenges in treatment delivery and efficacy.
Overall market sales
4D Molecular Therapeutics (4DMT) is a gene therapy company using its proprietary platform to create optimized viral vectors. Its value is determined by success in clinical development. The overall economic situation shown in this chart does not affect the scientific process, but it does provide a backdrop for attracting investment in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company 4D Molecular Therapeutics
4D Molecular Therapeutics is a clinical-stage gene therapy company using a proprietary platform to create and deliver optimized viral vectors. This projected revenue chart reflects confidence in its cutting-edge technology. Growth is driven by expectations for successful clinical trial results in ophthalmology, cardiology, and pulmonology.
%20sales%20of%20the%20company%204D%20Molecular%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-4D-Molecular-Therapeutics&v=1772513885788 "Schedule of future (projected) sales of the company 4D Molecular Therapeutics")
Future (projected) sales of companies in the market segment - Dna
4D Molecular Therapeutics is a biopharmaceutical company developing gene therapies based on optimized vectors (viruses) that deliver genes to targeted tissues, such as the retina or heart. This chart shows projected revenue for the entire DNA therapeutics sector, reflecting progress in creating more precise and safe treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513885817 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
4D Molecular Therapeutics is a biotechnology company developing gene therapy. Its future depends on success in clinical trials and scientific innovation. The positive economic environment and market growth forecast for this company create a favorable environment for attracting the investment vital for such capital-intensive research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513885869 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality 4D Molecular Therapeutics
4D Molecular Therapeutics is developing gene therapy using its proprietary AAV vector platform. Like many biotech companies in the R&D stage, it does not yet have revenue. This chart illustrates the cost of innovation, showing the investment required to advance its candidates through clinical trials.
Market segment marginality - Dna
4D Molecular Therapeutics is a biotech company specializing in gene therapy using a proprietary platform for creating and optimizing adeno-associated viral vectors. This chart reflects its financial performance. For a company in the research stage, outperforming competitors in profitability may be due to upfront payments from partners.
Market marginality as a whole
4D Molecular Therapeutics is a biotechnology company developing a platform for targeted gene therapy delivery. Its success depends not on the general economic cycles shown in this chart, but on scientific breakthroughs and clinical trial results. The ability to safely and effectively deliver genes to target tissues is key to their future.
Employees in the company, segment and market as a whole
Number of employees in the company 4D Molecular Therapeutics
4D Molecular Therapeutics is a biotechnology company developing a platform for targeted gene therapy delivery. This graph shows its growing team of scientists. This increase directly reflects progress in its numerous clinical programs and investments in this cutting-edge and sophisticated technology platform.
Share of the company's employees 4D Molecular Therapeutics within the market segment - Dna
4D Molecular Therapeutics is a biotech company developing gene therapy using proprietary viral vectors. Its core asset is its scientific platform and the team that refines it. This graph illustrates its focus on R&D: its small staff is typical for companies whose value lies in the potential of their innovative technologies.
Number of employees in the market segment - Dna
4D Molecular Therapeutics is a biotechnology company developing advanced gene therapy vectors that target specific tissues. This graph highlights innovation at the forefront of medicine. The growing scientific staff reflects progress in creating safer and more effective methods of delivering genetic material to treat a wide range of diseases.
Number of employees in the market as a whole
4D Molecular Therapeutics is a biotechnology company developing targeted gene therapy. Its team of highly skilled scientists is dedicated to creating drug delivery vectors. This employment chart highlights that in the world of cutting-edge science, growth is driven not by economic cycles, but by scientific breakthroughs and investments in innovation.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company 4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics is a biotech company developing a platform for creating optimized gene therapy vectors. The goal is to improve the efficacy and safety of treatments. This chart demonstrates the company's enormous value per scientist. Its market capitalization reflects the market's high valuation of its unique technology platform, not its current operations.
%20of%20the%20company%204D%20Molecular%20Therapeutics%20(FDMT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-4D-Molecular-Therapeutics-FDMT&v=1772513886151 "Chart of market capitalization per employee (in thousands of dollars) of the company 4D Molecular Therapeutics (FDMT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
4D Molecular Therapeutics is a biotech company developing a platform for targeted gene therapy delivery. In this cutting-edge field of medicine, value is determined by the technology's potential. This chart shows the significant premium the market places on their scientific platform and team, which are capable of creating drugs for previously incurable diseases.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513886157 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
4D Molecular Therapeutics develops gene therapy using its proprietary platform for creating delivery vectors. This metric exemplifies a business at the cutting edge of science. Its market capitalization is based on the potential of this unique technology. Even a small team of scientists could be worth hundreds of millions if their approach proves effective.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513886209 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company 4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics (FDMT) is a biotech company developing a gene therapy platform (AAV vectors). They are in the clinical stage and are not profitable. This chart shows the loss per employee. This reflects the high cost of R&D in creating new gene delivery vectors.
%20Chart%204D%20Molecular%20Therapeutics%20(FDMT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-4D-Molecular-Therapeutics-FDMT&v=1772513886258 "Company Profit Per Employee (in thousands of dollars) Chart 4D Molecular Therapeutics (FDMT)")
Profit per employee (in thousands of dollars) in the market segment - Dna
4D Molecular Therapeutics is a biotech company developing gene therapy using its own platform of vectors (delivery vehicles). The company has no profit, only R&D expenses. This metric reflects capital burn per employee, allowing them to compare the cost of their R&D platform with those of their competitors.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513886307 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
4D Molecular Therapeutics (FDMT) is a biotech company developing a gene therapy platform (AAV vectors). This is a deep R&D company. Like most companies at this stage, this graph shows a negative value—the "burn" of investment capital for each highly qualified scientist needed to advance their innovative platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513886367 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee 4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics is a biotech company developing gene therapy based on its innovative viral vector platform. This graph is typical for a clinical-stage company. The lack of revenue per employee means all resources are focused on research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-4D-Molecular-Therapeutics-FDMT&v=1772513886460 "Sales chart per company employee 4D Molecular Therapeutics (FDMT)")
Sales per employee in the market segment - Dna
4D Molecular Therapeutics (FDMT) is a biotech company developing a vector platform (AAV) for gene therapy delivery. They are working to create vectors that can be administered intravenously. This graph shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their cutting-edge R&D platform.
Sales per employee for the market as a whole
4D Molecular Therapeutics (FDMT) is a biopharmaceutical company developing a platform for the creation and delivery of gene therapies (AAV vectors) for the treatment of a wide range of diseases (eyes, lungs). This is an R&D business. The company has no commercial revenue. This metric does not yet reflect effectiveness.
Short shares by company, segment and market as a whole
Shares shorted by company 4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics (FDMT) is a biotech company developing targeted gene therapy. This chart shows bearish bets. Bears are betting on a high risk of clinical trial failure. The failure of a key candidate could lead to a stock collapse, as the company has no other sources of revenue.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-4D-Molecular-Therapeutics-FDMT&v=1772513886644 "Short Shares Chart for the Company 4D Molecular Therapeutics (FDMT)")
Shares shorted by market segment - Dna
4D Molecular Therapeutics (4DMT) is a biotech company developing "improved" viral vectors (delivery vehicles) for gene therapy. This metric measures pessimism. "Shorts" here represent a bet that their gene delivery platform will not prove superior or safe in the clinic.
Shares shorted by the overall market
4D Molecular Therapeutics (FDMT) is a biotech developing a vector platform (AAV) for targeted gene therapy delivery. This is a fundamental technology. This chart measures overall market pessimism. When fear dominates, investors often overlook the nuances of science. Biotech stocks without profits are the first to be sold, regardless of their long-term potential.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator 4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics (FDMT) is a biotech company focused on gene therapy. They use their platform (Therapeutic Vector Evolution) to create "improved" vectors (AAVs) for drug delivery to tissues (e.g., eyes, lungs). This chart measures hype. It shows "overheated" (above 70) due to positive R&D data or "oversold" (below 30) due to disappointing results.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-4D-Molecular-Therapeutics-FDMT&v=1772513886736 "RSI 14 indicator chart for the company's stock 4D Molecular Therapeutics (FDMT)")
RSI 14 Market Segment - Dna
4D Molecular (FDMT) is a biotech company that engineers *vectors*. Their platform (AAV) creates "improved" delivery vehicles for *gene therapy*. The RSI_14_Seg for "Dna" (biotech) shows the overall sentiment in the sector. The chart helps us understand: is FDMT's volatility a function of their platform, or is the entire sector overheated?
RSI 14 for the overall market
4D Molecular (FDMT) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast FDMT (4D Molecular Therapeutics)
4D Molecular (FDMT) is a biotech company developing gene therapy based on its "directed evolution" vector platform. This chart shows the average 12-month forecast, reflecting analysts' confidence in this technology and its potential to treat eye and heart diseases.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-FDMT-4D-Molecular-Therapeutics&v=1772513886886 "A chart showing analyst consensus forecasts for the expected stock price. FDMT (4D Molecular Therapeutics)")
The difference between the consensus estimate and the actual stock price FDMT (4D Molecular Therapeutics)
4D Molecular (FDMT) is a biotech company working on gene therapy delivery. Their R&D platform, Therapeutic Vector Evolution, creates vectors (AAVs) engineered to precisely deliver genes to target organs (eyes, lungs, heart). This chart shows how confident analysts are in their unique delivery platform and clinical pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-FDMT-4D-Molecular-Therapeutics&v=1772513886998 "A chart showing the difference between the consensus forecast and the actual stock price. FDMT (4D Molecular Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Dna
4D Molecular Therapeutics (FDMT) is a biotech company developing next-generation gene therapy vectors (delivery vehicles) to more precisely treat eye and lung diseases. This chart shows general expectations for the DNA technology sector, reflecting whether experts believe this R&D platform can deliver breakthroughs.
Analysts' consensus forecast for the overall market share price
4D Molecular Therapeutics (FDMT) is a gene therapy company. Their specialty is developing "smart" viral vectors (shells) designed to precisely deliver drugs to target tissues (eyes, lungs). This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough scientific R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index 4D Molecular Therapeutics
4D Molecular (FDMT) is a biotech company working at the forefront of gene therapy. Their specialty is vectors (AAVs): they engineer delivery viruses that precisely target the target (for example, specifically the retina). This graph is a pure R&D bet. It likely reflects the market's confidence in their delivery platform and their early clinical data in ophthalmology.
AKIMA Market Segment Index - Dna
4D Molecular (FDMT) is a clinical-stage biotech and a pioneer in gene therapy. The company uses its R&D platform (Therapeutic Vector Evolution) to create optimized AAV viruses targeting specific tissues (eyes, lungs). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this breakthrough (R&D platform) model (FDMT) differentiate it from the average pharma company?
The AKIM Index for the overall market
4D Molecular Therapeutics is a biotech company developing targeted gene therapy for eye, heart, and lung diseases. It utilizes directed evolution. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative gene delivery platform compares to overall economic trends.
